key: cord-0731044-me44sqyx
authors: Calabrese, Giulia; Licata, Gaetano; Gambardella, Alessio; Alfano, Roberto; Argenziano, Giuseppe
title: Is Periocular Dermatitis an Early Sign of COVID-19 Infection in Children?
date: 2021-05-11
journal: Dermatitis
DOI: 10.1097/der.0000000000000748
sha: e9dc30c6a8f955f9b6b0f89a24e48d445b77aea6
doc_id: 731044
cord_uid: me44sqyx

nan

To the Editor:

COVID-19 infection is caused by a recently identified pathogenthe severe acute respiratory syndrome coronavirus 2. 1 The respiratory system is the primary site of COVID-19 infection. Symptoms range from a mild flu-like syndrome to fulminant pneumonia and lethal respiratory distress. Recently, several cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 infection have been reported in the literature. The dermatologic findings include macular or maculopapular, vesicular, and urticarial rashes. Vascular lesions, including livedo, purpura, and necrosis, have also been reported. Pseudo-chilblains have been linked to COVID-19 infection in a select subset of patients. Timing of rashes ranges from a few days before to almost 2 weeks after diagnosis. 2 Kalner and Vergilis 3 have previously reported the case of a child with COVID-19 infection who presented with periorbital dermatitis. We are writing to describe a second case of periorbital dermatitis associated with COVID-19 infection that was diagnosed in our practice.

A 3-year-old White child, who was otherwise healthy, came to our department for evaluation of acute-onset periorbital dermatitis manifesting as erythematous, nonpruritic periorbital plaques. There was no conjunctival injection, and the child was asymptomatic (Fig. 1A) . He had not taken new medications, and his medical history was negative to allergies/atopy or other chronic skin disorders. Neither the child nor any family member was known to have COVID-19 infection. We initiated therapy with tacrolimus 0.1% ointment twice daily and scheduled a telemedicine follow-up. Two days after the visit, the mother reported that the child had developed fever, sore throat, and cough. Laboratory examinations included a complete blood count showing a mildly elevated white blood cell count, a C-reactive protein level of 8 mg/L (0.5-10 mg/L), and an erythrocyte sedimentation rate of 27 mm/h (0-21 mm/h), and the COVID-19 nasopharyngeal polymerase chain reaction test result was positive. Ten days after initial presentation, both the infection and the COVID-19 symptoms resolved according to the child's parents, and they decided to stop the therapy with tacrolimus ointment. The remission was confirmed by examination and negative nasopharyngeal COVID-19 polymerase chain reaction test result on day 14 (Fig. 1B) .

Cutaneous manifestations can be important clues to underlying infectious disease, especially when they appear in advance of fever and systemic symptoms. The pathogenesis of cutaneous features of COVID-19 is not well understood. Theories include viral

Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Applicability of an exaggerated forearm wash test for efficacy testing of two corticosteroids, tacrolimus and glycerol, in topical formulations against skin irritation induced by two different irritants

Skin symptoms in patients with atopic dermatitis using enzyme-containing detergents. A placebo-controlled study

Do topical corticosteroids modulate skin irritation in human beings? Assessment by transepidermal water loss and visual scoring

Are topical corticoids efficacious in acute irritant dermatitis: the evidence

From SARS to COVID-19: what we have learned about children infected with COVID-19

Cutaneous manifestations of COVID-19: an evidence-based review

Periorbital erythema as a presenting sign of COVID-19

Cutaneous manifestations of COVID-19: report of three cases and a review of literature

Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system

Dental implants have been developed to replace diseased or damaged teeth. Whereas traditional dental materials, such as gold crowns or mercury-containing amalgams, are well known causes of allergic contact dermatitis (ACD), dental implants are often made of titanium alloys. Dental implants consist of 3 parts: a fixture, an abutment, and a crown. During the surgical phase, the fixture is inserted into bone and is fitted with a healing cap during osseointegration. Once the tissues heal (approximately 4 months), the cap is removed and replaced with an abutment onto which a crown or a bridge is mounted.In 2019, the dental implant industry had a market value of more than $4 billion and is estimated to grow by 5% annually between 2020 and 2026. 1 Case reports of ACD manifesting as localized mucositis or burning mouth symptoms to titanium, palladium, or cobalt have been reported. [2] [3] [4] In vitro and in vivo studies have shown that titanium alloys are susceptible to corrosion in the